T. Ochi Lohmann

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

N. Reinmuth, F. Cappuzzo, T. Mekhail, 2019, The Lancet. Oncology.

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC.

N. Reinmuth, T. Mekhail, A. Morabito, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.